Digene strengthens diagnostic patents:
This article was originally published in Clinica
Executive Summary
US diagnostics company Digene has received a European patent for its Hybrid Capture technology. All of the company's tests are based on this technology, which uses signal amplification to detect as few as 100 molecules of DNA or RNA in a rapid format. The patent strengthens the company's protection for its human papillomavirus products and core technology, according to Beltsville, Maryland-based Digene.
You may also be interested in...
Vaccine Distribution Priorities To Rely On Governors, Not ACIP, HHS Secretary Azar Says
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi Grapples With Pandemic, Growing Clinical Trials, Implementing Acquisitions
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
ATAI Raises $125m Series C To Expand The Boundaries In Mental Health
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: